Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure

Trial Profile

A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs Netarsudil (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 15 Aug 2018 Topline results published in an Aerie Pharmaceuticals media release.
    • 15 Aug 2018 According to an Aerie Pharmaceuticals media release, a complete analysis of the study data will be presented at a future scientific congress.
    • 15 Aug 2018 Primary endpoint has been met. (Mean change from baseline in the mean diurnal trabecular outflow facility), according to an Aerie Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top